Bioworld feature

Summary:

Hong Kong-based company Mettactics is raising funds to develop a metastasis-on-a-chip (MoC) device for precision medicine. The device, based on microfluidic chip technology, can capture and study highly metastatic cancer cells. It provides a more realistic three-dimensional environment compared to traditional cell culture models, allowing researchers to replicate the tumor microenvironment and study cancer cell behavior more accurately. The device enables the capture and isolation of metastatic cells from patient samples, facilitating the development of targeted treatments. It offers advantages over mouse models, as it reduces time and manpower requirements. Mettactics plans to launch the device for research use and drug development. They envision controlling metastasis and are working on products for metastasis prevention and covering various cancer types.